SpecialK82
Ohio, USA
- Messages
- 993
- Location
- Ohio, USA
Looks like we may soon have a new option for receiving Rituximab in the US.
Check out Dr. Lapp's recent newsletter at http://drlapp.com/news/me-letter-december-2011/
for news about The Open Medicine Institute, Rituximab and more.
Hunter-Hopkins has joined with several well-known practices to form the Open Medicine Institute. Using EMR (Electronic Medical Records) we will be able to share anonymous information and medical records for the purpose of doing research as a group. We have already obtained more than $500,000 in grants from the Centers for Disease Control to study the Clinical Assessment of CFS. Patients who choose to participate will have their de-identified records transmitted to a central server so that a special team at the CDC can determine how various medical groups diagnose and manage persons with CFS/ME (PWCs). We hope that this will lead to a standard intake form and formal approach to CFS/ME that can be taught to many other healthcare providers. Participants in this project include Drs. Lapp and Black, Dr. Dan Peterson, Dr. Cindy Bateman, Dr. Rich Podell, and several others. Dr. Andy Kogelnick is the principal investigator.
The Open Medicine Institute has already begun discussions with the Norwegian study group, and we are hoping to soon offer trials of Rituximab in our office, pending approval by regulatory agencies and funding for the drug.
Check out Dr. Lapp's recent newsletter at http://drlapp.com/news/me-letter-december-2011/
for news about The Open Medicine Institute, Rituximab and more.
Hunter-Hopkins has joined with several well-known practices to form the Open Medicine Institute. Using EMR (Electronic Medical Records) we will be able to share anonymous information and medical records for the purpose of doing research as a group. We have already obtained more than $500,000 in grants from the Centers for Disease Control to study the Clinical Assessment of CFS. Patients who choose to participate will have their de-identified records transmitted to a central server so that a special team at the CDC can determine how various medical groups diagnose and manage persons with CFS/ME (PWCs). We hope that this will lead to a standard intake form and formal approach to CFS/ME that can be taught to many other healthcare providers. Participants in this project include Drs. Lapp and Black, Dr. Dan Peterson, Dr. Cindy Bateman, Dr. Rich Podell, and several others. Dr. Andy Kogelnick is the principal investigator.
The Open Medicine Institute has already begun discussions with the Norwegian study group, and we are hoping to soon offer trials of Rituximab in our office, pending approval by regulatory agencies and funding for the drug.
